Prevision Medicine, a Swiss precision oncology startup, secured $5.4 million in seed funding in a round led by ACE Ventures, the company announced September 24, 2026. GoHub Ventures, SICTIC and several oncology-focused angel investors also participated.
The Zurich-based company tests living tumor cells extracted from patient biopsies against more than 100 drugs and drug combinations, then delivers a ranked treatment report within 72 hours. The platform currently focuses on blood cancers and glioblastoma, an aggressive brain tumor with notoriously poor treatment outcomes.
Prevision plans to deploy the capital toward regulatory clearances and reimbursement pathways in Europe while building relationships with molecular tumor boards and insurance providers. The company, incorporated in September 2024, is still in research-use phase but aims to move toward clinical adoption as validation data accumulates.
Testing treatments before patients do
The core technology, called PrevisionOne, relies on image-based single-cell analysis to measure how patient-derived cancer cells respond to approved drugs, experimental compounds and off-label therapies. Critically, the system also tests healthy cells from the same patient, allowing researchers to rank treatments based on selectivity. The goal is to identify drugs that kill cancer aggressively while sparing normal tissue.
According to the company, blood malignancies like acute myeloid leukemia and multiple myeloma typically generate results in about three days. Glioblastoma samples take closer to five days. According to the company, the platform has processed roughly 2,000 patient samples through partnerships with more than 20 hospitals, though that figure may have grown since it was last disclosed.
Prevision expanded its multiple myeloma testing panel in March 2026 to evaluate up to 56 drugs and combinations, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies and antibody-drug conjugates. The test remains classified as research-use-only while the company works through validation and regulatory processes.
A team with exits under its belt
CEO and co-founder Philip Zimmermann brings prior startup experience to the role. He previously co-founded Nebion, a genomics software company that Immunai acquired in mid-2021. After the deal, Zimmermann served as Immunai's vice president of business development for Europe before launching Prevision.
Chief scientific officer Yannik Severin co-invented the underlying platform as the first PhD student in the lab of Berend Snijder, a professor at ETH Zürich who chairs Prevision's board. Snijder developed the pharmacoscopy technique that powers the platform and has his own exit on record: he co-founded Allcyte, which Exscientia acquired in 2021.
Chief business officer Valentin Matillon previously worked in senior finance roles at SOPHiA GENETICS, including during the company's NASDAQ debut.
Clinical data and a validation grant
Prevision's approach draws on published research, including a 2024 paper in Haematologica that described pharmacoscopy-guided treatment selection in AML patients who had exhausted standard options. A 2022 study in Cancer Discovery reported clinical benefit in advanced hematologic cancers, while a 2023 Nature Cancer paper examined drug response variability in multiple myeloma.
In September, the startup was selected for Level 3 of the Future of Health Grant, a clinical validation initiative run by Swiss insurer CSS and the EPFL Innovation Park. Prevision was chosen from more than 600 applicants. The 12-month program will support real-world evidence generation as the platform expands into hospital settings.
Competition in functional precision medicine
Prevision is entering a small but active field. SEngine Precision Medicine, based in the U.S., offers the PARIS test, a CLIA-certified functional assay that presented data on rare cancers at the 2025 AACR meeting. Known Medicine operates a 3D organoid platform for patient-specific drug screening, working with both clinical and biopharma partners. EMPIRI runs a live-tissue testing platform in collaboration with MD Anderson and other cancer centers.
The underlying problem is well documented. Close to half of cancer patients do not respond to their initial treatment, a reality that drives both financial waste and delayed care. Prevision's pitch is that what was once a clinically validated but economically impractical technique has now been refined into something hospitals and payers might actually adopt.
Whether that holds true will depend less on the science than on reimbursement timelines, regulatory hurdles and how quickly oncologists can be convinced to incorporate functional testing into treatment decisions that remain, for now, largely driven by genomics and clinical guidelines.
